Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06668792
Recruiting
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 · Russia · 20 sites
Registry update: 4 Feb 2025
NCT06483100
Recruiting
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Phase 2 · United States · 1 site
Registry update: 6 Aug 2026
NCT06711705
Recruiting
Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 20 Feb 2026
NCT06679101
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, China, Czechia, Germany, Spain, France, United Kingdom, Greece, Ireland, Israel, India, Italy, Japan, South Korea, Norway, Poland, Taiwan, United States, South Africa · 166 sites
Registry update: 22 Apr 2026
NCT07028970
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Not applicable · China · 6 sites
Registry update: 19 Jun 2025
NCT06732232
Recruiting
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 13 Dec 2024
NCT06561854
Recruiting
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · France · 46 sites
Registry update: 18 Dec 2024
NCT05272826
Recruiting
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Phase 2 · Canada · 7 sites
Registry update: 31 Aug 2026
NCT06718270
Recruiting
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Early phase 1 · China · 1 site
Registry update: 12 Dec 2024
NCT06669247
Recruiting
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Phase 1/2 · Australia, United Kingdom · 9 sites
Registry update: 5 Aug 2026
NCT06465316
Recruiting
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Phase 1 · United States · 17 sites
Registry update: 27 Oct 2026
NCT06623630
Recruiting
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Phase 1 · United States · 1 site
Registry update: 11 Mar 2026
NCT06768489
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Phase 1 · Australia, Spain, Israel, Netherlands, United States · 16 sites
Registry update: 25 Sept 2026
NCT06580002
Recruiting
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Phase 2 · United States · 1 site
Registry update: 14 Jul 2026
NCT06477783
Recruiting
Study on the Clinical Efficacy of Teclistamab and Talquetamab
Not applicable · Belgium · 17 sites
Registry update: 25 Sept 2026
NCT06697483
Recruiting
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Not applicable · China · 4 sites
Registry update: 25 Nov 2024
NCT05846880
Recruiting
VitD3 Supplementation in Patients With Multiple Myeloma
Early phase 1 · United States · 1 site
Registry update: 8 Apr 2025
NCT06700395
Recruiting
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
Phase 1 · China · 2 sites
Registry update: 6 Dec 2024
NCT06645678
Recruiting
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 · South Korea, Singapore · 7 sites
Registry update: 3 Dec 2025
NCT06245629
Recruiting
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Not applicable · Sweden · 1 site
Registry update: 29 Nov 2024

Ordered by registry start date. Freshness and sponsorship never change the order.